As many other countries, Japan is working on development of personalized and precision medicine. This paper explains Japan's policies regarding personalized and precision medicine, including data collection, supports for its development and its insurance coverage such as its process and criteria and describes four drugs and companion diagnosis. Especially as for the insurance coverage, Japan has not examined the cost-effectiveness of personalized and precision medicine and its impact on healthcare expenditures. On the other hand, since the United Kingdom considers cost-effectiveness in considering the insurance coverage, the United Kingdom limits the use of Imatinib due to cost-effectiveness while Japan does not limit it.
Introduction
As advanced technologies minimize the involved cost and time, genome analysis is starting to be used for the development of personalized and precision medicine (PPM) and its accompanying diagnostics.
Many countries are working to develop PPM. The United States has the Precision Medicine Initiative
and Million Veteran Program; the United Kingdom has Genomics England; China, South Korea, and Saudi Arabia have all started their own projects; and Japan is also working to develop PPM. In all these countries, though, the development of PPM may be hampered by insurance questions.
Governments may be reluctant to cover PPM and its accompanying tests with public insurance because they are expensive and may increase healthcare expenditures. This paper looks at Japan's PPM policies, as well as the country's experience covering PPM and its companion tests with public insurance. For the sake of comparison, the paper also considers the development of PPM in the United Kingdom.
Personalized and Precision Medicine: Strategy
The Japanese government supports the development of PPM, as clearly stated in the Japan Revitalization Strategy 2016 and the Healthcare Policy Strategy. Based on these strategies, the 
Related Policies
The development of PPM heavily depends on the amount of genome data available. Japan is collecting genome data mainly through its three largest biobanks-Bio Bank Japan, Tohoku Medical
Megabank, and National Center Bio Bank Network-which work together. Bio Bank Japan, the largest of the three, plans to collect data from 300,000 people. Japan supports clinical trials and clinical research on genomic medical care and plans to select seven core hospitals in 2017 where it will support the provision of genomic medical treatment. 5 In 2016, the total budget for these plans [was ¥11.36 billion ($103 million). 6 The National Cancer Center started the SCRUM-Japan Project, which helps hospitals and pharmaceutical companies develop PPM for cancer. There are no government regulations on genetic testing.
In the United Kingdom, the Department of Health started the 100,000 Genomes Project in 2012, which targeted 70,000 patients in the National Health Service (NHS) who suffer from rare diseases or cancer, along with 30,000 of their family members. The UK government's budget for this initiative was £310 million ($403 million) for the period 2013-17. 7 The size of the United Kingdom's biobank and data collection budget is much larger than that of Japan's. The United Kingdom also established the Genomics England Clinical Interpretation Partnership (which includes clinicians and researchers) and the Genomics Expert Network for Enterprises (GENE) Consortium (which enables partner companies to access gene data collected under Genomics England and to develop new testing and medication). In 2015, the Precision Medicine Catapult was initiated to accelerate the development of PPM. 
Insurance Coverage
In Japan, based on the Health Insurance Act, public insurance generally covers medication (see Figure   1 ). First, the medication's quality, effectiveness, and safety must be approved based on the Law on 
Examples of Approved Drugs and Companion Diagnostics in Clinical Practice
In Japan, cancer was the biggest cause of death over the past decade. Among patients newly diagnosed with cancer, colorectal cancer is the most common, followed by gastric, lung, prostrate, and breast cancers. 13 Since the treatment demands for these are enormous, this paper considered approved drugs and companion diagnostics for these cancers that are already covered by public insurance in Japan (see Table 1 ). For example, Japan approves Herceptin for patients whose HER2 is excessive. Herceptin, Erbitux, and Gleevec were approved in Japan after being approved in the United
States and the European Union. Gefitinib was approved first in Japan and then in the U.S. and EU due to its advanced effectiveness. The Drug Pricing Organization notifies applicants of the draft.
Applicants accept it.
Applicants appeal the decision.
The Drug Pricing Organization examines the appeal and determines a draft of the drug pricing.
The Drug Pricing Organization notifies applicants of a result of the examination.
The Central Social Insurance Medical Council determines the drug pricing Table 3 shows the price of approved drugs in Japan and the United Kingdom, which are quite expensive. For example, the monthly expenditure of patients who have to take just one Gefitinib a day is more than ¥180,000 ($1,636), and for those who have to take 400 milligrams (mg) of Gleevec every day, it is more than ¥295,860 ($2,688). Among people 70 years and under, the copayment rate is 30 percent; for those who are 70 to 74 years old it is 20 percent; and for those above 74 years it is 10 percent. Thus, people do not pay the exact same amount. In addition, Japan has a High-Cost Medical Expense Benefit that has established a cap on the drug expenditures of the insured. Except for Gefitinib, drug prices in Japan are more expensive than those in the United Kingdom. These results are similar to that of another research study that showed the average price of a new drug in 
Other Genetic Testing
Japan's public insurance also covers the genetic testing mentioned in Table 5 . Purpose is to figure out a method of treating and conducting a precise pathological diagnosis. Hematopoietic tumor genetic testing ¥21,000 ($191) Purpose is to figure out a method of treating leukemia patients. Polymorphism of UGT1A1 gene ¥21,000 ($191) Purpose is to figure out the dose amount of irinotecan hydrochloride (anti-cancer drug). Irinotecan hydrochloride is for lung-cancer and metastatic-colorectal-cancer patients.
Coverage of the above tests has been expanded. Since MHLW needs to financially support patients who suffer from incurable diseases based on the Act on Medical Care for Rare Disease
